JP2023527563A5 - - Google Patents

Info

Publication number
JP2023527563A5
JP2023527563A5 JP2022573609A JP2022573609A JP2023527563A5 JP 2023527563 A5 JP2023527563 A5 JP 2023527563A5 JP 2022573609 A JP2022573609 A JP 2022573609A JP 2022573609 A JP2022573609 A JP 2022573609A JP 2023527563 A5 JP2023527563 A5 JP 2023527563A5
Authority
JP
Japan
Prior art keywords
approximately
antibody
preparation
administration
april
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022573609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527563A (ja
JP7843248B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035011 external-priority patent/WO2021243298A1/en
Publication of JP2023527563A publication Critical patent/JP2023527563A/ja
Publication of JP2023527563A5 publication Critical patent/JP2023527563A5/ja
Priority to JP2026056121A priority Critical patent/JP2026126199A/ja
Application granted granted Critical
Publication of JP7843248B2 publication Critical patent/JP7843248B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022573609A 2020-05-29 2021-05-28 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法 Active JP7843248B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026056121A JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062704831P 2020-05-29 2020-05-29
US62/704,831 2020-05-29
PCT/US2021/035011 WO2021243298A1 (en) 2020-05-29 2021-05-28 Methods of treating iga nephropathy with an april binding antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026056121A Division JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2023527563A JP2023527563A (ja) 2023-06-29
JP2023527563A5 true JP2023527563A5 (enExample) 2024-06-06
JP7843248B2 JP7843248B2 (ja) 2026-04-09

Family

ID=78722933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022573609A Active JP7843248B2 (ja) 2020-05-29 2021-05-28 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
JP2026056121A Pending JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026056121A Pending JP2026126199A (ja) 2020-05-29 2026-03-30 ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法

Country Status (11)

Country Link
US (1) US20210379183A1 (enExample)
EP (1) EP4157339A4 (enExample)
JP (2) JP7843248B2 (enExample)
KR (1) KR20230017223A (enExample)
CN (1) CN115996748A (enExample)
AU (1) AU2021279035A1 (enExample)
BR (1) BR112022024262A2 (enExample)
CA (1) CA3179812A1 (enExample)
IL (1) IL298370A (enExample)
MX (1) MX2022014995A (enExample)
WO (1) WO2021243298A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN116322775A (zh) 2020-06-02 2023-06-23 阿雷斯贸易股份有限公司 IgA肾病治疗的相关方法
AU2023262513A1 (en) 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof
AU2023366516A1 (en) 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024099272A1 (zh) * 2022-11-07 2024-05-16 信瑞诺医药（上海）有限公司 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合
WO2026050274A2 (en) * 2024-08-27 2026-03-05 Paragon Therapeutics, Inc. April binding proteins, compositions, and methods of use thereof
WO2026067804A1 (zh) * 2024-09-30 2026-04-02 信立泰(成都)生物技术有限公司 一种抗april抗体或其抗原结合片段及用途
WO2026122561A2 (en) 2024-12-03 2026-06-11 Otsuka America Pharmaceutical, Inc. Methods of treating sjögren's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
CA2681728C (en) * 2007-03-27 2015-12-22 Zymogenetics, Inc. Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
RU2481824C2 (ru) * 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
WO2010100056A2 (en) * 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
KR20180066241A (ko) * 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
US12103979B2 (en) * 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11034768B2 (en) * 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途

Similar Documents

Publication Publication Date Title
JP2024174927A5 (enExample)
US7740842B2 (en) Stable liquid formulations of antibodies
JP2024026214A5 (enExample)
ES2253326T3 (es) Composicion farmaceutica de acido 2-(4-isobutilfenilo)propionico.
TW202146049A (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP6353577B2 (ja) 組み合わせ組成物
JP2022532927A5 (enExample)
AU2016280555A1 (en) Anti-CGRP antibody formulation
AU2004317520B2 (en) Stable injectable diclofenac compositions
JP2016514132A5 (enExample)
GB2112641A (en) The use of peptides as medicaments
JP2002521329A5 (enExample)
EP3681483A1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
EP3964197A1 (en) Liquid pharmaceutical composition
WO2022135395A1 (zh) 稳定的抗体制剂及其制备方法和应用
KR20200014738A (ko) 안정한 항-osmr 항체 제형
RU2020111574A (ru) Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
JP2020531523A5 (enExample)
EP2604264B1 (en) Pharmaceutical composition for treating viral diseases
US20220110917A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
AU2016346703B2 (en) Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
JP2025072464A (ja) 改善された凍結乾燥製剤
JPH03135918A (ja) 免疫賦活剤
CA3139341A1 (en) Stable albuvirtide compositions
JP2025531290A (ja) カボテグラビルおよびリルピビリンを用いる小児患者のｈｉｖの治療